Back to INSMView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA10/27/2020
Arikayce liposomal
Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.
Orphan
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.Phase 3
Pseudomonas Aeruginosa Infection
Treprostinil Palmitil Inhalation PowderPhase 3
Pulmonary Hypertension
Brensocatib 25 mgPhase 3
Non-Cystic Fibrosis Bronchiectasis
LAI 590 mgPhase 3
NTM Lung Infection Due to MAC
Treprostinil PalmitilPhase 3
Pulmonary Hypertension
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts